Decision

Early access to medicines scheme (EAMS) scientific opinion: Nivolumab

This publication was withdrawn on

The positive scientific opinion for nivolumab has lapsed because it has been granted a marketing authorisation.

Information on the EAMS scientific opinion given to nivolumab, including the public assessment report.